What is the treatment for acute urticaria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Acute Urticaria

For acute urticaria, second-generation non-sedating H1 antihistamines are the first-line treatment, with dose escalation up to 4 times the standard dose for inadequate response. 1, 2

First-Line Treatment

  • Non-sedating second-generation H1 antihistamines are the mainstay of therapy for acute urticaria, with options including:

    • Cetirizine 10 mg daily
    • Loratadine 10 mg daily
    • Fexofenadine
    • Desloratadine
    • Levocetirizine 1, 2
  • Patients should be offered at least two different non-sedating antihistamines, as responses and tolerance vary between individuals 2

  • For mild cases (hives covering <10% body surface area), continue with standard dose of oral antihistamines 1

Second-Line Treatment

  • For moderate cases (10-30% body surface area) or inadequate response to standard dose, increase the antihistamine dose up to 4 times the standard dose when benefits outweigh risks 1, 2

  • First-generation antihistamines should generally be avoided due to sedation and anticholinergic effects 3

  • Cooling antipruritic lotions (calamine or 1% menthol in aqueous cream) can provide symptomatic relief 4, 2

Third-Line Treatment

  • For severe cases (>30% body surface area) or inadequate response to increased antihistamine dosing, systemic corticosteroids (prednisone 0.5-1 mg/kg/day) are recommended until hives resolve to grade 1 1

  • However, recent evidence suggests that the addition of corticosteroids to antihistamines may not provide additional benefit in some cases of acute urticaria 5

  • Consider same-day dermatology consultation for severe cases 1

Special Considerations

  • Assess for airway compromise in cases with angioedema 1

  • Consider epinephrine for severe symptoms affecting breathing in cases with angioedema, as it alleviates pruritus, urticaria, and angioedema through its action on alpha and beta-adrenergic receptors 1, 6

  • Identify and minimize aggravating factors such as:

    • Overheating
    • Stress
    • Alcohol
    • Certain medications (aspirin, NSAIDs, codeine) 1, 2
  • NSAIDs should be avoided in aspirin-sensitive patients with urticaria 4, 2

  • ACE inhibitors should be avoided in patients with angioedema without weals 4, 2

Treatment Algorithm Based on Severity

  1. Mild Acute Urticaria (<10% BSA)

    • Standard dose second-generation H1 antihistamine 1
    • Consider topical corticosteroids if needed 1
  2. Moderate Acute Urticaria (10-30% BSA) or Inadequate Response

    • Increase antihistamine dose up to 4x standard dose 1, 2
    • Try alternative second-generation antihistamine if inadequate response 2
  3. Severe Acute Urticaria (>30% BSA) or Inadequate Response

    • Systemic corticosteroids (prednisone 0.5-1 mg/kg/day) 1
    • Consider dermatology consultation 1
    • Rule out systemic hypersensitivity with CBC with differential and CMP 1
  4. Acute Urticaria with Angioedema and Respiratory Compromise

    • Epinephrine for severe symptoms affecting breathing 1, 6
    • Continue antihistamines and add systemic corticosteroids 3

Common Pitfalls and Caveats

  • Avoid first-generation antihistamines due to sedation and potential to convert minor reactions into hemodynamically significant events 3

  • The course of acute urticaria is typically self-limited, with most cases resolving within 3 weeks 7

  • While combination therapy with H1 and H2 antihistamines has been suggested for some refractory cases, evidence does not justify routine addition of H2-antihistamines to H1-antihistamine treatment 8

  • For patients with renal impairment, avoid acrivastine in moderate renal impairment, and halve the dose of cetirizine, levocetirizine, and hydroxyzine 2

  • For patients with hepatic impairment, avoid mizolastine in significant hepatic impairment 2

References

Guideline

Acute Urticaria Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Urticaria Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Severe Hives (Urticaria)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of acute urticaria: A systematic review.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2024

Research

Antihistamines in urticaria and angioedema.

Clinical allergy and immunology, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.